<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="3" ids="16335">Adenosine</z:chebi> kinase (ADK) is the major negative metabolic regulator of the endogenous neuroprotectant and homeostatic bioenergetic network regulator <z:chebi fb="3" ids="16335">adenosine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>We used three independent experimental approaches to determine the role of ADK as a molecular target for predicting the brain's susceptibility to <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>First, when subjected to a middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model of focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, transgenic fb-Adk-def mice, which have increased ADK expression in striatum (164%) and reduced ADK expression in cortical forebrain (65%), demonstrate increased striatal <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (126%) but almost complete protection of cortex (27%) compared with <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) controls, indicating that cerebral injury levels directly correlate to levels of ADK in the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Second, we demonstrate abrogation of <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> (LPS)-induced ischemic preconditioning in transgenic mice with brain-wide ADK overexpression (Adk-tg), indicating that ADK activity negatively regulates LPS-induced tolerance to <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Third, using adeno-associated virus-based vectors that carry Adk-sense or -antisense constructs to overexpress or knockdown ADK in vivo, we demonstrate increased (126%) or decreased (51%) <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, respectively, 4 weeks after injection into the striatum of WT mice </plain></SENT>
<SENT sid="5" pm="."><plain>Together, our data define ADK as a possible therapeutic target for modulating the degree of <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced brain injury </plain></SENT>
</text></document>